Sung Sup Park

Title: Innovations of Sung Sup Park in Antibody Development

Introduction

Sung Sup Park is a notable inventor based in Taejon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies. His work focuses on creating therapeutic solutions for autoimmune diseases.

Latest Patents

Sung Sup Park holds a patent for a "Humanized antibody specific for human 4-1BB." This invention is directed towards humanized antibodies that specifically bind to the protein 4-1BB. The antibodies are developed by grafting the complementarity determining regions (CDRs) of a mouse monoclonal antibody to human 4-1BB, along with further amino acid replacements. The resulting humanized antibody exhibits high affinity for human 4-1BB and shows sequence similarity to human antibodies. This innovation can be utilized in pharmaceutical compositions to treat autoimmune diseases and suppress immune responses with minimal side effects. He has 1 patent to his name.

Career Highlights

Sung Sup Park is associated with LG Chemical Ltd., where he continues to advance his research in antibody development. His work has the potential to significantly impact the treatment of autoimmune diseases, providing new avenues for therapeutic interventions.

Collaborations

He has collaborated with notable colleagues, including Chang-Yuil Kang and Sung Kwan Yoon, to further enhance the research and development of innovative antibody therapies.

Conclusion

Sung Sup Park's contributions to the field of biotechnology, particularly through his patent on humanized antibodies, highlight his role as an influential inventor. His work promises to pave the way for new treatments in autoimmune diseases, showcasing the importance of innovation in medical science.